Day One Biopharmaceuticals, Inc. Common Stock
DAWN US23954D1090
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -35% | 23% | -28% | -13% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Merendino Lauren CCO |
6.77 USD |
3,766 Sold |
25,485 USD |
15/08/2025 | 18/08/2025 |
| Dubow Adam SEC |
6.77 USD |
4,365 Sold |
29,538 USD |
15/08/2025 | 18/08/2025 |
| Bender Jeremy CEO |
6.77 USD |
16,058 Sold |
108,666 USD |
15/08/2025 | 18/08/2025 |
| York Charles N Ii COO |
6.77 USD |
4,106 Sold |
27,786 USD |
15/08/2025 | 18/08/2025 |
| Merendino Lauren CCO |
6.26 USD |
3,927 Sold |
24,575 USD |
15/05/2025 | 16/05/2025 |
| Dubow Adam SR OFF |
6.26 USD |
4,552 Sold |
28,486 USD |
15/05/2025 | 16/05/2025 |
| York Charles N Ii CFO |
6.26 USD |
4,282 Sold |
26,796 USD |
15/05/2025 | 16/05/2025 |
| Dubow Adam SR OFF |
6.26 USD |
4,552 Sold |
28,486 USD |
15/05/2025 | 16/05/2025 |
| Merendino Lauren CCO |
6.26 USD |
3,927 Sold |
24,575 USD |
15/05/2025 | 16/05/2025 |
| Bender Jeremy CEO |
6.26 USD |
13,964 Sold |
87,385 USD |
15/05/2025 | 16/05/2025 |